Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/avid-and-beyond-lessons-learned-M6nfMDKIBb
References (27)
-
Singh Singh (1994)
Implantable cardioverter defibrillators: Note the ultimate gold standard for gauging therapy of VT/fibrillationAm J Cardiol, 73
-
A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near fatal ventricular arrhythmias
N Engl J Med, 337
-
Newman Newman, Suave Suave, Herre Herre (1992)
Survival after implantation of a cardioverter defibrillatorAm J Cardiol, 69
-
Böcker Böcker, Haverkamp Haverkamp, Block Block (1996)
Comparison of d, 1 ‐sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery diseaseCirculation, 94
-
Böcker Böcker, Block Block, Borggrefe Borggrefe (1997)
Defibrillators are superior to antiarrhythmic drugs in treatment of ventricular tachyarrhythmiasEur Heart J, 18
-
Winkle Winkle, Mead Mead, Ruder Ruder (1989)
Long term outcome with the automatic implantable cardioverter defibrillatorJ Am Coll Cardiol, 13
-
Cox Cox (1989)
Patient selection criteria and results of surgery for refractory ischemic ventricular tachycardiaCirculation, 79
-
Zipes Zipes (1994)
Implantable cardioverter defibrillator. Lifesaver or a device looking for a diseaseCirculation, 89
-
Böcker Böcker, Breithardt Breithardt, Block Block (1994)
Management of patients with ventricular tachyarrhythmias: Does an optimal therapy existPACE, 17
-
Fogoros Fogoros, Ellison Ellison, Bonnet Bonnet (1989)
Actual incidence and pattern of recurrence of shocks following implantation of the automatic implantable cardioverter defibrillatorPACE, 9
-
Moss Moss, Hall Hall, Cannom Cannom (1996)
Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmiaN Engl J Med, 335
-
Halperin Halperin, Brodsky Brodsky, Lancaster Lancaster (1997)
Prognostic value of baseline electrophysiology studies—The Antiarrhythmics Versus Implantable Defibrillators (AVID) TrialCirculation, 96(8)suppl
-
Zipes Zipes (1995)
Are implantable cardioverter defibrillators better than the conventional antiarrhythmic drugs for survivors of cardiac arrestCirculation, 91
-
Bigger Bigger (1997)
for The CABG‐Patch Trial Investigators: Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgeryN Engl J Med, 337
-
Mitchell Mitchell (1997)
Clinical trials of antiarrhythmic drugs in patients with sustained ventricular tachyarrhythmiasCurr Opin Cardiol, 12
-
Saksena Saksena, Madon Madon, Lewis Lewis (1996)
Implantable cardioverter defibrillators are preferable to drugs as primary therapy in sustained ventricular tachyarrhythmiasProg Cardiovasc Dis, 38
-
Lehmann Lehmann, Saksena Saksena (1991)
for the NASPE Policy Conference Committee. Implantable cardioverter defibrillators in cardiovascular practice: Report of the policy conference of the North American Society of Pacing and ElectrophysiologyPACE, 14
-
Steinberg Steinberg, Cannom Cannom, Marinchak Marinchak (1997)
Dilated cardiomyopathy versus coronary artery disease in patients with VT/VF: Differences in presentation and outcome in the antiarrhythmics versus implantable defibrillators (AVID) registryCirculation, 96(8)suppl
-
Thomas Thomas, Moser Moser, Smutka Smutka (1988)
Implantable defibrillation: Eight years clinical experiencePACE, 11
-
Kim Kim (1993)
Implantable defibrillator therapy: Does it really prolong lifeHow can we prove it? Am J Cardiol, 71
-
Anderson Anderson (1996)
Implantable defibrillators are preferable to pharmacologic therapy for patients with ventricular tachyarrhythmias: An antagonist's viewpointProg Cardiovasc Dis, 37
-
Fogoros Fogoros, Fielder Fielder, Ellison Ellison (1987)
The automatic implantable cardioverter defibrillator in drug refractory ventricular arrhythmiasAnn Intern Med, 107
-
Mirowski Mirowski, Reid Reid, Winkle Winkle (1983)
Mortality in patients with implanted automatic defibrillatorsAnn Intern Med, 98
-
Kim Kim (1995)
Evolution of the management of malignant ventricular tachyarrhythmias: The roles of drug therapy and implantable defibrillatorsAm Heart J, 130
-
Kim Kim, Hallstrom Hallstrom, Love Love (1997)
Comparison of clinical characteristics and frequency of implantable defibrillator use between randomized patients in the antiarrhythmics vs implantable defibrillators (AVID) trial and nonrandomized registry patientsAm J Cardiol, 80
-
Pinski Pinski, Yao Yao, Cook Cook (1997)
Baseline prognostic indicators in patients with sustained ventricular tachyarrhythmias: The Antiarrhythmics Versus Implantable Defibrillator (AVID) Trial RegistryCirculation, 96(8)suppl
-
Powell Powell, Fuchs Fuchs, Finkelstein Finkelstein (1993)
Influence of implantable cardioverter defibrillators and long‐term prognosis of survivors of out‐of‐hospital cardiac arrestCirculation, 88
- Publisher
- Wiley
- Copyright
- Copyright © 1998 Wiley Subscription Services, Inc., A Wiley Company
- ISSN
- 0896-4327
- eISSN
- 1540-8183
- DOI
- 10.1111/j.1540-8183.1998.tb00122.x
- Publisher site
- See Article on Publisher Site
Abstract
The implantable cardioverter defibrillator (ICD) has been approved by the Food and Drug Administration (FDA) since 1985 and is widely used in practice. Until recently, however, the efficacy of the ICD has depended on a large published series of retrospective studies analyzing ventricular tachycardia and fibrillation patients. The recently published Antiarrhythmics Versus Implantable Defibrillator (AVID) trial is the first prospective randomized trial to show clearly that the ICD is more effective than drug therapy (amiodarone or sotalol) in patients who have survived an out‐of‐hospital cardiac arrest or have syncopal or hemodynamically significant ventricular tachycardia. The survival advantages probably hold true only for patients with an ejection fraction under 35% who have either coronary disease or other forms of cardiomyopathy. The survival advantage in this trial—which was halted prematurely because of the results noted—was short‐lived (2.8 months) and expensive. The results of this trial will clearly define the role of the ICD in everyday clinical practice and will be of invaluable benefit to patients, physicians, and insurers alike. The results of the AVID trial, as well as other postevent and pre‐event trials, are summarized in this article. A number of sub studies have already resulted from the AVID study and are also presented.
Journal
Journal of Interventional Cardiology – Wiley
Published: Jun 1, 1998